secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amneal Pharmaceuticals, Inc. (AMRX)
CIK:        0001723128
Form:       8-K
Filed at:   2022-08-05T23:59:59+00:00
Accession:  0001723128-22-000028
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amneal Q2 2022: net loss $121M, revenue +5% to $559M; Opana settlement charge $263M
--------------------------------------------------------------------------------

- Q2 2022 net revenue $559M (+5% YoY); GAAP net loss $121M vs net income $15M in Q2 2021.
- Adjusted EBITDA $135M (-6% YoY); adjusted diluted EPS $0.19 vs $0.23 in prior year.
- Pre-tax charge of $263M for Opana ER antitrust litigation settlement recorded.
- 2022 adjusted EBITDA guidance updated; specific figure not disclosed in provided excerpt.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1723128/000172312822000028/0001723128-22-000028-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1723128/000172312822000028/amrx-20220805.htm
  HTML page:      https://secwatch.observer/filing/0001723128-22-000028

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer